| Lysosomal Storage Disease |
1 |
1 |
| Glycogen Storage Disease (GSD) Type II |
0 |
0.91 |
| Muscle |
0 |
0.23 |
| Genomic Medicine |
0 |
0.2 |
| Spinal Muscular Atrophy |
0 |
0.18 |
| Skeletal Myoblasts |
0 |
0.17 |
| Muscle Biopsy |
0 |
0.16 |
| Aminotransferase |
0 |
0.15 |
| Liver |
0 |
0.15 |
| Myalgia |
0 |
0.15 |
| Biologic Therapy |
0 |
0.14 |
| Gene Therapy |
0 |
0.13 |
| Blood-Brain Barrier |
0 |
0.12 |
| Liver Biopsy |
0 |
0.12 |
| Blood |
0 |
0.11 |
| Pain Management |
0 |
0.11 |
| Child |
0 |
0.1 |
| Weakness |
0 |
0.1 |
| Blood Vessel |
0 |
0.09 |
| Brain |
0 |
0.08 |
| Cardiomyopathy |
0 |
0.08 |
| Healthcare and Medical Technology |
0 |
0.08 |
| Cerebral Aneurysm |
0 |
0.07 |
| Central Nervous System |
0 |
0.06 |
| Clinical Research |
0 |
0.06 |
| Genetics |
0 |
0.06 |
| Heart |
0 |
0.06 |
| Hypertension |
0 |
0.06 |
| Metabolic Myopathy |
0 |
0.06 |
| Myopathy |
0 |
0.06 |
| Biopsy |
0 |
0.04 |
| Birth |
0 |
0.04 |
| Disability |
0 |
0.04 |
| Limb |
0 |
0.04 |
| Magnetic Resonance Imaging |
0 |
0.04 |
| Newborn |
0 |
0.04 |
| Rare Diseases |
0 |
0.04 |
| Skeletal |
0 |
0.04 |
| Aneurysm |
0 |
0.03 |
| Bone Marrow |
0 |
0.03 |
| Muscular Atrophy |
0 |
0.03 |
| Antihypertensive Agents |
0 |
0.02 |
| Autopsy |
0 |
0.02 |
| Biomarker |
0 |
0.02 |
| Board Certification |
0 |
0.02 |
| Bone |
0 |
0.02 |
| Diaphragm |
0 |
0.02 |
| Disease-Modifying Therapy |
0 |
0.02 |
| Drug Development |
0 |
0.02 |
| Exercise |
0 |
0.02 |
| Financial Reimbursement |
0 |
0.02 |
| Jobs |
0 |
0.02 |
| Metabolism |
0 |
0.02 |
| Multidisciplinary Team |
0 |
0.02 |
| Neurodegenerative Diseases |
0 |
0.02 |
| Neuroimaging |
0 |
0.02 |
| Neuron |
0 |
0.02 |
| Physical Medicine and Rehabilitation (PMR) |
0 |
0.02 |
| Physical Therapy |
0 |
0.02 |
| Preventive Screening |
0 |
0.02 |
| Referral |
0 |
0.02 |
| Respiratory Failure |
0 |
0.02 |
| Revenue and Practice Management |
0 |
0.02 |
| Sleep |
0 |
0.02 |
| Tissue |
0 |
0.02 |